Truqap with Zytiga and ADT improved radiographic progression-free survival in patients with PTEN-deficient prostate cancer compared to placebo. The CAPitello-281 trial involved 1,012 patients, showing ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real ...
A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination. Researchers at Baylor College of Medicine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback